Samuel C. Blackman Sells 30,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the transaction, the insider now owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Day One Biopharmaceuticals Stock Up 3.4 %

NASDAQ:DAWN opened at $14.13 on Friday. Day One Biopharmaceuticals, Inc. has a 52 week low of $9.67 and a 52 week high of $18.07. The stock’s 50-day moving average price is $14.35 and its 200-day moving average price is $14.64. The stock has a market capitalization of $1.24 billion, a PE ratio of -5.63 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $0.90 million. Sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -1.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its position in Day One Biopharmaceuticals by 4.2% during the fourth quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock worth $61,857,000 after acquiring an additional 169,463 shares during the period. Braidwell LP raised its position in shares of Day One Biopharmaceuticals by 13.5% during the 4th quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after purchasing an additional 500,000 shares during the last quarter. Deerfield Management Company L.P. Series C raised its position in shares of Day One Biopharmaceuticals by 65.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock worth $40,281,000 after purchasing an additional 1,157,825 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Day One Biopharmaceuticals by 28.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after buying an additional 472,654 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Day One Biopharmaceuticals by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock worth $33,575,000 after buying an additional 336,281 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on DAWN. Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price objective for the company from $11.00 to $24.00 in a report on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, August 1st. JPMorgan Chase & Co. reduced their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, July 30th. Finally, Piper Sandler reiterated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.